A woman happily resting head on a mans shoulder

Join the Vallania Study to help develop blood tests to detect cancer early.

Early detection matters

5-year survival rate 6X higher

Every day, cancer claims nearly 2,000 lives in the U.S. alone. Many cancers are detected too late, when treatments are less likely to succeed.

Finding cancer early can make a world of difference in outcomes and survival. For example, when colon cancer is found before it spreads, the 5-year survival rate is more than 6x higher.1

The Vallania Study

The Vallania Study is part of our multi-cancer research program focused on developing next-generation blood tests to detect cancer in its earliest, most treatable stages.

The Vallania Study is enrolling about 5,400 individuals aged 30 and above who are willing to provide a blood sample. The study aims to develop blood tests that can provide accurate, convenient and patient-friendly options for cancer screening.

Freenome’s clinical studies are named for employees’ loved ones who have battled cancer. This study honors a Freenome scientist’s mother who battled pancreatic cancer.

Who can participate

Cancer participants

Our study is looking for people who have been diagnosed with cancer and have not yet received treatment.

Non-cancer participants

We are also looking for participants who do not have signs or symptoms of cancer, or a known cancer diagnosis.

For more information: www.clinicaltrials.gov

Older woman with glasses smiling Older woman with glasses smiling

How it works

Those who participate in the non-cancer group will receive a follow up via phone or medical records review one year after blood draw.

How it works

  1. Talk to your healthcare provider to find out if you qualify to enroll in the Vallania Study
  2. Get a standard blood draw. No medications or treatments are part of this study.
  3. Receive your stipend and our thanks

Frequently asked questions

What is the purpose of the Vallania study?

The Vallania Study is part of Freenome’s multi-cancer research program. The study aims to compare blood samples from both cancer and non-cancer patients to understand patterns for certain types of cancers. The goal is to build a test that provides an accurate, convenient, and patient-friendly option to screen for cancers. This includes some cancers without any current recommended screening options.

Why is the study named the Vallania Study?

Starting in 2021, Freenome began naming all clinical studies in honor of employees’ loved ones who fought cancer. The Vallania Study is named in honor of Natalia Vallania, the mother of a Freenome scientist.

What is the time commitment required to participate in this study?

Participation in the Vallania Study requires a standard blood draw and answering a few questions about your medical background.

If I participate, how will I receive my test results?

Any diagnostic tests and results that may be part of your individual medical care will continue to come directly from your doctor. As the Freenome product is under development, you will not receive a Freenome test report as part of this study.

Will I be compensated?

Yes, you will be compensated if you enroll and complete the requirements of the study.

Which cancer types are being studied in the Vallania Study?

The Vallania Study is looking at multiple cancer types. Cancer types studied may differ by study location, please contact us for details.

Scientist holding a rack of test tubes

About Freenome

Freenome, a biotechnology company, has pioneered a comprehensive platform for early cancer detection using a routine blood draw. The company combines its expertise in molecular biology with advanced computational biology and machine learning to recognize disease-associated patterns among billions of biomarkers.

  1. “Promoting Early Detection and Treatment of Cancer”. Centers for Disease Control and Prevention. Accessed November 21, 2021. https://www.cdc.gov/cancer/ncccp/priorities/early-detection-treatment.htm